Sutro Biopharma (STRO) Income from Non-Controlling Interests (2019 - 2025)
Sutro Biopharma (STRO) posted Income from Non-Controlling Interests of -$4000.0 for Q2 2025, up 97.01% sequentially from -$134000.0 in Q1 2024.
Sutro Biopharma (STRO) Income from Non-Controlling Interests (2019 - 2025) Analysis & Trends
Sutro Biopharma has reported Income from Non-Controlling Interests for 7 years, with the latest figure at -$4000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4,000.00 |
| Mar 31, 2024 | -134,000.00 |
| Jun 30, 2023 | 123,000.00 |
| Mar 31, 2023 | 511,000.00 |
| Jun 30, 2022 | -204,000.00 |
| Mar 31, 2022 | -838,000.00 |
| Jun 30, 2021 | -45,000.00 |
| Mar 31, 2021 | -129,000.00 |
| Jun 30, 2020 | 370,000.00 |
| Mar 31, 2020 | -137,000.00 |
| Jun 30, 2019 | 157,000.00 |
| Mar 31, 2019 | 103,000.00 |